Clinical Trials Logo

Bullous Pemphigoid clinical trials

View clinical trials related to Bullous Pemphigoid.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05061771 Withdrawn - Bullous Pemphigoid Clinical Trials

Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP)

ARREST-BP
Start date: May 6, 2022
Phase: Phase 3
Study type: Interventional

A phase III two-part study of nomacopan, a bifunctional inhibitor of complement component C5 and leukotriene B4 (LTB4), for the treatment of moderate and severe bullous pemphigoid. There is evidence that both terminal complement activation (via C5) and the lipid mediator LTB4 may have a central role in driving the disease. In this study patients will be randomized to receive either nomacopan plus oral corticosteroids (OCS) or placebo plus OCS for a treatment period of 24 weeks. OCS will be tapered over the course of the treatment if the symptoms of disease improve.